Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hana Pharm Co., Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This study was designated to investigate the quality of recovery after transurethral bladder resection. Because, patients undergoing transurethral bladder resection are mostly old age, and because of catheter-related bladder discomfort are common after transurethral bladder resection, study on the quality of recovery after transurethral bladder resection seems to be meaningful. In general, sevoflurane is commonly used as an anesthetic agent for general anesthesia of transurethral bladder resection. The purpose of this study is to investigate whether remimazolam is not inferior to sevoflurnane in terms of quality of recovery after transurethral bladder resection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sevoflurane | Active Comparator | General anesthesia using sevoflurane |
|
| Remimazolam | Experimental | General anesthesia using remimazolam |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sevoflurane | Drug | Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50. |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of recovery -15 score at postoperative day 1 | Quality of recovery-15 questionnaire, which consists 15 questions. The score ranges from 0 to 150. The higher the score, the better the quality of recovery. | postoperative day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Catheter related bladder discomfort | Catheter related bladder discomfort is assessed as none, mild, moderate and severe. | 5 minutes, and 1 hour after post-anesthesia circuit unit arrival. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eunah Cho, Pf. | KangbukSamsung Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Eunah Cho | Seoul | 03181 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000077149 | Sevoflurane |
| C522201 | remimazolam |
| ID | Term |
|---|---|
| D008738 | Methyl Ethers |
| D004987 | Ethers |
| D009930 | Organic Chemicals |
| D006845 | Hydrocarbons, Fluorinated |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Remimazolam | Drug | Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50. |
|
| D006846 |
| Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |